The Lilly MDR-TB PartnershipLocal Action, Global Impact

World Bank Donor Forum Paris, France

20 May 2008

Patrizia CarlevaroHead, International Aid Unit

Eli Lilly and Company

Facts & Figures TB kills close to two million people every year

TB kills one person every 20 seconds

4600 people will die of TB by the end of today -- most of whom are in their most productive working years (ages 15 to 54)

2 billion people are infected with TB worldwide -- 1 in 10 will become sick with active TB

12 million people worldwide with HIV/AIDS-TB co-infection

One-third of AIDS patients die of TB, making TB the leading cause of death among AIDS patients

Nearly 500,000 of the 9.2 million new cases of TB every year are multidrug-resistant

China and India account for half the world’s MDR-TB cases

Highest MDR-TB incidences are in countries of the former Soviet Union

MDR-TB prolonged and complex

treatment can result in poor patient compliance and development of drug resistance

Decline in worker productivity to the order of US$13 billion annually

Lilly has organized health professionals, businesses, academic institutions, and communities in a comprehensive US$135 million MDR-TB program

Global MDR-TB Challenge:Businesses & communities at risk

Since 2003, Lilly has lead a comprehensive approach to fighting MDR-TB through

MISSION: to combat the growing MDR-TB pandemic and to support the Global Plan

to Stop TB.

Awareness and Prevention

Treatment, Training and Surveillance

Research

Transferring Technology

Community Support and Patient Advocacy

Reaching patients throughout the world

Reaching patients throughout the world

The Partners

Aspen Pharmacare, South Africa International Council of Nurses International Federation of Red Cross &

Red Crescent Societies International Hospital Federation Harvard Medical School & Partners in Health Hisun Pharmaceutical, China Purdue University, USA

Results Educational Fund Shasun Chemicals and Drugs, India SIA International, Russia Stop TB Partnership TB Alert and TB Survival Project U.S. Centers for Disease Control & Prevention World Economic Forum World Health Organization World Medical Association

Transfer of Technology Share Lilly’s specific and general

manufacturing knowledge

Create self-sustaining centers of manufacturing excellence capable of providing additional products and employment

Support reliable generic producers to ensure expanded multi-source availability of the two drugs

Offer manufacturing firms in MDR-TB “hot spots” (China, India, Russia, South Africa) the technology to produce two second line TB drugs

Technical training in manufacturing and Good Business Practices with the support from Purdue University

Provide Lilly staff on-site for technical assistance/training

Transferring Technology

360 degree approach: examples

Healthcare Professional Education Program

International Council of Nurses (ICN)Scope/reach: more than 13 million nurses worldwide Sample 1 activity: Training of Trainers Sample 2 activity: Development of framework and advocacy for TB and

MDR-TB curriculum in nursing schools

World Medical Association (WMA) Scope/reach: 7 million physicians worldwide

Sample 1 activity: Develop distance learning course for physicians addressing the clinical aspects of MDR-TB

Sample 2 activity: Conduct in-country training with local medical associations

International Hospital Federation (IHF)Scope/reach: 50,000 hospital facilities worldwide Sample activity: Development of MDR-TB control manuals and

disseminated to 40,000 public and private hospitals and clinics

360 degree approach: examples

Community Support and Patient AdvocacyInternational Federation of Red Cross and Red Crescent (IFRC) Sample activity: Community support to people living with MDR-TB to ensure

better access to care and improved compliance

Awareness and PreventionTB Survival Project and TB Alert Sample activity: Patient-led initiative to raise awareness and engage patients

and their families worldwide

STOP TB Partnership Sample activity: Advocacy and awareness campaign involving football star

Luis Figo as goodwill ambassador

Research and Development Establishment of a not-for-profit early phase drug to integrate medicinal

chemistry expertise from the pharmaceutical industry with academic expertise in chemistry, microbiology and TB (basic biology genetics and molecular biology)

Includes collaboration with the Infectious Disease Research Institute (Seattle, USA), National Institute of Allergy and Infectious Diseases (USA), Global Alliance for TB Drug Development, etc.

TB and MDR-TB in the workplacePartnership with the World Economic Forum (WEF) Develop a Global Awareness Toolkit for Tuberculosis/MDR-TB in the Workplace and

disseminate through WEF member companies Provide educational material targeting employees and in-plant healthcare staff Pilot-tested by the WEF in India and being adapted for other high-burden countries

with large business communities

Advocacy and awareness in the workplacePartnership with the Global Business Coalition (GBC) GBC scope/reach: 220 cross-cutting multinational companies worldwide (e.g., Coca

Cola Company, Citibank, General Motors, Deutsche Post World Net, L’Oréal, Siemens, etc.)

Distributed 400,000 card decks with TB awareness/advocacy messages in Beijing train stations (target: migrant workers)

360 degree approach: examples

Contact Information

Dr Patrizia CarlevaroHead, International Aid UnitEli Lilly and CompanyGeneva, Switzerlandcarlevaro_patrizia@lilly.com

www.lilly.comwww.lillymdr-tb.com